scholarly journals Effect of High‐Sucrose and High‐Fructose Diets on Adipose Tissue Dysfunction and Metabolic Syndrome

2018 ◽  
Vol 32 (S1) ◽  
Author(s):  
Anil Sakamuri ◽  
Sugeedha Jeyapal ◽  
Suryam Reddy Kona ◽  
Sailaja Pothana ◽  
Ahamed Ibrahim
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Adipose Tissue Dysfunction ◽  
High Fructose ◽  
High Sucrose

scholarly journals Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2515 ◽  
Author(s):  
Marleen M. J. van Greevenbroek ◽  
Casper G. Schalkwijk ◽  
Coen D.A. Stehouwer
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Low Grade ◽  
Pharmacological Interventions ◽  
Obesity Epidemic ◽  
The Metabolic Syndrome ◽  
Adipose Tissue Dysfunction ◽  
Recent Developments ◽  
Low Grade Inflammation ◽  
The Complement System

The ongoing worldwide obesity epidemic makes the metabolic syndrome an increasingly important entity. In this review, we provide a short background on the metabolic syndrome, we discuss recent developments in the three main options that have been identified for intervention in the metabolic syndrome, i.e. lifestyle and surgical and pharmacological interventions, and we focus on different views in the literature and also include our own viewpoints on the metabolic syndrome. In addition, we discuss some emerging treatment targets for adipose tissue dysfunction and low-grade inflammation, i.e. activation of the inflammasome and the complement system, and consider some selected opportunities for intervention in these processes.

Mechanisms of adipose tissue dysfunction of stages of metabolic syndrome

2013 ◽  
Vol 0 (2(43)) ◽  
pp. 10-14
Author(s):  
О. С. Ларін ◽  
М. Л. Кирилюк ◽  
О. Е. Третяк ◽  
М. С. Черенько ◽  
Л. В. Щекатурова ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Adipose Tissue Dysfunction

scholarly journals Adipose tissue dysfunction in obese horses with equine metabolic syndrome

2019 ◽  
Vol 51 (6) ◽  
pp. 760-766 ◽  
Author(s):  
A. Reynolds ◽  
J. A. Keen ◽  
T. Fordham ◽  
R. A. Morgan
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Equine Metabolic Syndrome ◽  
Adipose Tissue Dysfunction

scholarly journals The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?

2021 ◽  
Vol 22 (2) ◽  
pp. 742
Author(s):  
Simone Bini ◽  
Laura D’Erasmo ◽  
Alessia Di Costanzo ◽  
Ilenia Minicocci ◽  
Valeria Pecce ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Lipid Metabolism ◽  
Potential Role ◽  
Cardiometabolic Diseases ◽  
Adipose Tissue Dysfunction ◽  
The Relationship

Angiopoietin-like proteins, namely ANGPTL3-4-8, are known as regulators of lipid metabolism. However, recent evidence points towards their involvement in the regulation of adipose tissue function. Alteration of adipose tissue functions (also called adiposopathy) is considered the main inducer of metabolic syndrome (MS) and its related complications. In this review, we intended to analyze available evidence derived from experimental and human investigations highlighting the contribution of ANGPTLs in the regulation of adipocyte metabolism, as well as their potential role in common cardiometabolic alterations associated with adiposopathy. We finally propose a model of ANGPTLs-based adipose tissue dysfunction, possibly linking abnormalities in the angiopoietins to the induction of adiposopathy and its related disorders.

scholarly journals 192: Adipose tissue dysfunction in a model of developmental programming of metabolic syndrome

2012 ◽  
Vol 206 (1) ◽  
pp. S97-S98
Author(s):  
Egle Bytautiene ◽  
Debdeep Banerjee ◽  
Talar Kechichian ◽  
Huaizhi Yin ◽  
Elena Sbrana ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Developmental Programming ◽  
Adipose Tissue Dysfunction

scholarly journals Overexpression of TRB3 Gene in Adipose Tissue of Rats with High Fructose-induced Metabolic Syndrome

2008 ◽  
Vol 55 (4) ◽  
pp. 747-752 ◽  
Author(s):  
Xiu-ping BI ◽  
Hong-wei TAN ◽  
Shan-shan XING ◽  
Zhi-hao WANG ◽  
Meng-xiong TANG ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
High Fructose

scholarly journals Adipose Tissue Dysfunction in Nascent Metabolic Syndrome

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Andrew A. Bremer ◽  
Ishwarlal Jialal
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Low Grade ◽  
The Metabolic Syndrome ◽  
Adipose Tissue Dysfunction ◽  
Increased Risk ◽  
Subcutaneous Adipose ◽  
Low Grade Inflammation

The metabolic syndrome (MetS) confers an increased risk for both type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Moreover, studies on adipose tissue biology in nascent MetS uncomplicated by T2DM and/or CVD are scanty. Recently, we demonstrated that adipose tissue dysregulation and aberrant adipokine secretion contribute towards the syndrome’s low-grade chronic proinflammatory state and insulin resistance. Specifically, we have made the novel observation that subcutaneous adipose tissue (SAT) in subjects with nascent MetS has increased macrophage recruitment with cardinal crown-like structures. We have also shown that subjects with nascent MetS have increased the levels of SAT-secreted adipokines (IL-1, IL-6, IL-8, leptin, RBP-4, CRP, SAA, PAI-1, MCP-1, and chemerin) and plasma adipokines (IL-1, IL-6, leptin, RBP-4, CRP, SAA, and chemerin), as well as decreased levels of plasma adiponectin and both plasma and SAT omentin-1. The majority of these abnormalities persisted following correction for increased adiposity. Our data, as well as data from other investigators, thus, highlight the importance of subcutaneous adipose tissue dysfunction in subjects with MetS and its contribution to the proinflammatory state and insulin resistance. This adipokine profile may contribute to increased insulin resistance and low-grade inflammation, promoting the increased risk of T2DM and CVD.

scholarly journals Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue

2018 ◽  
Vol 2018 ◽  
pp. 1-21 ◽  
Author(s):  
Sofia Dias ◽  
Sílvia Paredes ◽  
Laura Ribeiro
Keyword(s):  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Visceral Obesity ◽  
Atherogenic Dyslipidemia ◽  
Adipose Tissue Dysfunction ◽  
Treatment Focus ◽  
Underlying Mechanisms ◽  
Approved Drugs

Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity, and adipogenesis. The clinical outcomes of adipose tissue modulation by these drugs, as well as differences of major importance for clinical practice between drugs of the same class, were identified. Whether solutions to these issues will be found in further adjustments and combinations between drugs already in use or necessarily in new advances in pharmacology is not known. To better understand the effect of drugs used in dyslipidemia and obesity on adipose tissue not only is challenging for physicians but could also be the next step to tackle cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document